AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

LaserView is involved in eye surgery services, self-described as a reference in this field.

LaserView

Acerta Pharma, an affiliate of AstraZeneca, develops and delivers targeted novel transformational medicines for patients with hematological malignancies.  Acerta Pharma uses innovative approaches to discover, develop, and deliver targeted medicines, focusing on innovative clinical strategies and resistance biology.

Acerta Pharma

AIER Eye Hospital is a global eye care provider with a network of hospitals and centers across multiple countries, offering ophthalmology services and medical education.

Metric
Company Name	AbbVie Inc.	LaserView	Acerta Pharma	AIER Eye Hospital
Symbol	ABBV
MSH ID	COM:ABBVIE	BR:COM:LASERVIEW	COM:ACERTA-PHARMA	COM:AIERCHINA:EN
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - General	Medical Services	Pharmaceutical	Eye Care and Ophthalmology
Country	US	BR	NL	CN
Stage				Series A
Employee Count	50K
Website	abbvie.com	laserview.com.br	acerta-pharma.com	en.aierchina.com
LinkedIn
Founders

Metric
Market Cap	296.91B
Enterprise Value
Monthly Web Traffic	1.18M
Web Traffic Growth	0.51
Valuation
Raised Capital	15B	1.45M

Metric
Revenue	54.32B
Revenue (LTM)
Revenue (NTM)
Gross Profit	45.54B
EBITDA	18.10B
Operating Income	17.43B
Net Income	4.86B
EPS	2.75
Diluted EPS	2.74
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.72
Operating Profit Margin	0.27
EBITDA Margin	0.33
Net Profit Margin	0.11
Return on Equity	0.57
Return on Assets	0.04
Return on Capital Employed	0.15

COM:ABBVIE

AbbVie Inc.

Last Close

171.73

22/11 21:00

Market Cap

296.91B

Beta: -

Volume Today

11.33M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	46.58
P/B Ratio	25.09
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.36
EV Multiple	17.44

Metric
Days Sales Outstanding	75.54
Days Payables Outstanding
Days Inventory Outstanding	102.41
Operating Cycle	181.71
Cash Conversion Cycle	179.57
Asset Turnover	0.40

Metric
Operating Cash Flow	22.84B
Free Cash Flow	22.06B
Cash Flow to Debt	0.38
Operating Cash Flow/Sales	0.42
Free Cash Flow Yield	0.08

Metric
Cash & Equivalents	12.81B
Accounts Receivable	66M
Inventory	4.10B
Goodwill	32.29B
Debt to Capitalization	0.91
Debt to Assets	0.45
Current Ratio	0.96
Quick Ratio	0.83

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.14
SG&A to Revenue